Profound Research LLC
Oceanside, California, 92056, United States
NCT Number: NCT06038474
This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Interventional
Phase 2
Oceanside, California, 92056, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Autologous T-cells expressing a chimeric antigen receptor directed to BCMA
Time frame: Day -59 to Day 50
Results will be descriptive. Safety and tolerability endpoints will include descriptive statistics of AEs and SAEs. Patients must be followed until all AEs have resolved to Grade 2 or less except for lymphopenia and alopecia.
Time frame: Day -59 to Month 12
Assessment of Systemic Lupus Erythematosus Disease Activity Index 2000 from baseline administration at various timepoints up to month 12 follow up visit. A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity.
Time frame: Day -59 to Month 12
Assessment of whether participants meet the Systemic Lupus Erythematosus Responder Index (SRI) criteria (Yes/No) at various timepoints up to month 12 follow up visit.
Time frame: Day -59 to Month 12
Assessment of whether participants meet the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) criteria (Yes/No) at various timepoints up to month 12 follow up visit.
Time frame: Day -59 to Month 12
Assessment of Physician Global Assessment (PGA) from baseline administration at various timepoints up to month 12 follow up visit. A total score can fall between 0.0 and 3.0, with a higher score representing a more significant degree of disease activity.
Cartesian Therapeutics
Industry
Acronym: SLE-001
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06799520
Alopecia, Alopecia Areata
Sofia, Bulgaria
View Trial DetailsNCT05458622
Autoimmune Diseases, Connective Tissue Diseases
Brest, France
View Trial DetailsNCT06144710
Autoimmune Diseases, Connective Tissue Diseases
Bengbu, Anhui, China
View Trial DetailsNCT05411016
Autoimmune Diseases, Connective Tissue Diseases
Kutsukake, Aichi-ken, Japan
View Trial Details